Gilead Sciences GILD Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.96B+4.4% | $7.93B+4.7% | $7.77B+3.0% | $7.08B+1.8% | $6.67B-0.3% | ||
| $1.45B-6.2% | $1.62B+2.7% | $1.57B-0.3% | $1.5B-2.8% | $1.54B-0.8% | ||
| $5.52B+7.6% | $6.3B+5.2% | $6.2B+3.8% | $5.58B+3.2% | $5.13B-0.1% | ||
| 79.2%+2.3pp | 79.5%+0.4pp | 79.8%+0.7pp | 78.8%+1.0pp | 76.9%+0.1pp | ||
| $1.45B+15.3% | $1.79B-5.9% | $1.36B-5.3% | $1.37B-0.9% | $1.26B-8.5% | ||
| $4.37B-1.3% | $5.94B+16.1% | $4.44B-33.3% | $4.61B+6.9% | $4.43B-59.8% | ||
| $2.59B+15.6% | $1.98B-19.1% | $3.33B+275% | $2.47B-6.4% | $2.24B+152% | ||
| 37.2%+3.6pp | 25%-7.4pp | 42.8%+31.1pp | 34.9%-3.1pp | 33.6%+98.2pp | ||
| $240M-7.7% | $255M+2.4% | $256M+7.6% | $254M+7.2% | $260M+2.4% | ||
| $235M+172% | $349M— | $569M+85.9% | $208M+159% | -$328M-460% | ||
| $2.58B+56.5% | $2.08B-4.1% | $3.64B+281% | $2.43B+18.3% | $1.65B+137% | ||
| $559M+67.4% | $0-100% | $589M+298% | $468M+6.8% | $334M+206% | ||
| $2.02B+53.7% | $2.18B+22.4% | $3.05B+144% | $1.96B+21.4% | $1.32B+132% | ||
| 29%+9.3pp | 27.5%+4.0pp | 39.3%+22.7pp | 27.7%+4.5pp | 19.7%+82.1pp | ||
| $1.61+54.8% | $1.74+22.5% | $2.43+143% | $1.56+20.9% | $1.04+131% | ||
| $1.63+53.8% | $1.76+23.9% | $2.46+146% | $1.57+21.7% | $1.06+132% | ||
| 1.3B-0.4% | 1.3B0.0% | 1.3B0.0% | 1.3B+0.3% | 1.3B+1.0% | ||
| 1.2B-0.3% | 1.2B-0.2% | 1.2B-0.3% | 1.2B-0.2% | 1.2B-0.1% | ||
| $107M-57.7% | $539M— | $170M-66.3% | $61M+60.5% | $253M-93.9% | ||
| $596M-0.5% | $597M-0.2% | $596M0.0% | $598M+0.3% | $599M+0.5% | ||
| $179M+190% | —— | $659M+214% | -$178M-7.2% | -$199M+72.5% | ||
| $93M-4.1% | $90M-5.3% | $90M-4.3% | $93M-5.1% | $97M+3.2% | ||
| -$67M+36.2% | -$95M— | —— | -$162M-95.2% | -$105M-246% | ||
| -$134M-69.6% | —— | $333M+306% | $292M+907% | -$79M-220% | ||
| -$702M-188% | —— | $811M+434% | -$166M+4.6% | -$244M-39.4% | ||
| -$29M+94.7% | -$134M— | -$122M— | -$1.3B-11.0% | -$552M-165% | ||
| $52M-76.7% | $123M-45.6% | $515M+506% | $175M+150% | $223M+396% | ||
| -$5M+58.3% | $36M-75.3% | $368M+546% | -$81M-526% | -$12M-132% | ||
| -$4.24B-23.7% | -$1.26B— | -$1.49B-8.0% | -$1.57B+46.9% | -$3.43B-152% | ||
| $1.77B+527% | -$1.84B-716% | -$427M+39.9% | -$2.12B-589% | -$415M+81.2% | ||
| $2.54B+44.8% | $3.33B+11.8% | $4.11B-4.7% | $827M-37.6% | $1.76B-20.8% | ||
| -$183M-101% | -$267M-353% | -$89M-3.5% | -$33M+62.9% | -$91M+23.5% | ||
| $17M-26.1% | -$11M+68.6% | —— | —— | $23M+560% | ||
| $419M-42.6% | $230M-34.3% | $435M+45.0% | $527M+427% | $730M+82.5% | ||
| $1.04B+3.0% | $994M+2.2% | $1.01B+2.2% | $994M+2.3% | $1.01B+2.0% | ||
| $525M— | $1.38B— | $270M— | $2B— | $0-100% | ||
| $109M-60.1% | $609M+712% | $167M-70.7% | $21M-86.2% | $273M-93.2% | ||
| $117M+12.5% | $205M+39.5% | $147M+4.3% | $107M-17.7% | $104M-1.0% | ||
| $166M-34.1% | $32M-81.5% | $97M-1.0% | $27M+440% | $252M+72.6% | ||
| $36M— | $23M— | $17M— | $15M— | $0-100% | ||
| -$179M-1.7% | -$63M-34.0% | -$137M-67.1% | -$64M-77.8% | -$176M-51.7% | ||
| $2.52B— | $340M— | $219M— | $295M— | $0-100% | ||
| $2.77B+57.0% | $8M+14.3% | $9M-92.0% | $9M-99.5% | $1.76B— | ||
| $1.37B-0.5% | $1.58B-3.5% | $1.35B-3.5% | $1.49B+10.4% | $1.38B-9.3% | ||
| $6.96B+4.4% | $7.93B+4.7% | $7.77B+3.0% | $7.08B+1.8% | $6.67B-0.3% | ||
| $218M+4.3% | $230M+3.6% | $230M+6.5% | $225M+7.1% | $209M+11.8% | ||
| $2.68B+14.8% | $2.07B-18.6% | $3.42B+248% | $2.57B-6.4% | $2.33B+155% | ||
| 38.5%+3.5pp | 26.2%-7.5pp | 44%+31.0pp | 36.2%-3.2pp | 35%+98.2pp | ||
| $2.59B+15.6% | $1.98B-19.1% | $3.33B+275% | $2.47B-6.4% | $2.24B+152% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gilead Sciences's revenue?
- Gilead Sciences (GILD) generated $29.7B in revenue over the trailing twelve months, up 3.5% year over year.
- Is Gilead Sciences profitable?
- Gilead Sciences reported $9.2B in net income over the trailing twelve months, a 31.0% net margin.
- What are Gilead Sciences's profit margins?
- Gross margin is 79.4% and operating margin is 34.9%, with a 31.0% net margin.
- What is Gilead Sciences's earnings per share?
- Gilead Sciences's diluted EPS over the trailing twelve months is $7.34.
- Where does Gilead Sciences's income statement data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
